Mira Precision Health Launches ToxNav Advantage to Support Oncology Treatment Decisions

Mira Precision Health, specialists in precision medicine diagnostics, has announced the U.S. launch of ToxNav Advantage, an AI-based clinical decision support platform, at the 2026 ASCO Gastrointestinal Cancers Symposium. The software is designed to help oncologists assess and manage treatment-related toxicity risk by analyzing patient-specific data alongside therapy characteristics. Mira intends for ToxNav Advantage to support more informed treatment planning, particularly for gastrointestinal cancers where adverse effects can limit dose intensity or lead to early discontinuation.

The launch comes as oncology teams face growing complexity in balancing efficacy and tolerability across expanding treatment options. Key features include comprehensive analysis of gene variants, rapid turnaround time for actionable results and clear optimized reports that are clinician-friendly with actionable insights that prevent life-threatening toxicities. By emphasizing prospective toxicity insights, Mira’s approach reflects broader interest in using AI to support individualized care planning. For health systems, tools that reduce avoidable adverse events may also help improve quality metrics and resource utilization.

Posted by MedCloudInsider Editors on 01/05/2026